Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07568509 · ClinicalTrials.gov registry record · Early Phase 1
Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease
A Early Phase 1 study, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT07568509: Recruiting Early Phase 1 study, sponsored by Massachusetts General Hospital.
NCT07568509 is a Early Phase 1 study that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07568509, a Early Phase 1 study, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
An open-labeled, interventional pilot trial, 10 youth with AVP-D and 10 PD matched for age, sex, and BMI will be recruited from Pediatric Endocrinology and Neuroendocrinology at Massachusetts General Hospital and in the community. This study tests the hypothesis that oral estrogen/progestin will stimulate endogenous oxytocin release in control subjects. Eligible participants will receive two tablets in a single administration containing a total of 1 mg of norethindrone acetate 70 mcg of ethinyl estradiol. Sampling for blood and saliva will take place at baseline and approximately 24 hours following study drug administration. Neuropsychological assessment (anxiety, mood and emotion regulation; impulse control; aberrant eating behaviors; social cognition and functioning; quality of life) will be assessed at baseline to characterize the study population.
Interventions
- DRUG Norethindrone Acetate-Ethinyl Estradiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-05 |
| Est. Completion | 2027-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07568509
The ClinicalTrials.gov registry entry for NCT07568509 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Norethindrone Acetate-Ethinyl Estradiol is the first listed.
NCT07568509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07568509 about?
NCT07568509 is a clinical study titled "Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease". An open-labeled, interventional pilot trial, 10 youth with AVP-D and 10 PD matched for age, sex, and BMI will be recruited from Pediatric Endocrinology and Neuroendocrinology at Massachusetts General Hospital and in the community. This study tests the hypothesis that oral estrogen/progestin will sti...
What is the current status of trial NCT07568509?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2026-05. Estimated completion is 2027-04.
What interventions are being tested in trial NCT07568509?
The interventions under investigation include: Norethindrone Acetate-Ethinyl Estradiol (DRUG).
Who is sponsoring clinical trial NCT07568509?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.